Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.66 |
| ▸ | NPC1 | O15118 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | ECE1 | P42892 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | STAT1 | P42224 | 2/20 | 0.49 |
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
| ▸ | KDM4B | O94953 | 1/20 | 0.49 |
| ▸ | KDM5C | P41229 | 1/20 | 0.49 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MYC | P01106 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30006556 | 1.00 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2ECE1KDM4E | |
| SCHEMBL27886900 | 0.83 | ECE1 (0.51) | RAB9ANPC1SMN1; SMN2ECE1KDM4E | |
| SCHEMBL1339930 | 0.82 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2KDM4EKDM4A | |
| SCHEMBL26643227 | 0.81 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2ECE1KDM4E | |
| SCHEMBL31597120 | 0.81 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2KDM4ESTAT1 | |
| SCHEMBL2800244 | 0.79 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2KDM4ESTAT1 | |
| SCHEMBL22383456 | 0.79 | ALDH1A1 (0.61) | RAB9ANPC1SMN1; SMN2POLBHTT | |
| SCHEMBL23742612 | 0.78 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2KDM4EGAA | |
| SCHEMBL13475977 | 0.76 | GRM5 (0.54) | RAB9ASMN1; SMN2ECE1KDM4EPOLB | |
| SCHEMBL1093303 | 0.76 | SMN1; SMN2 (0.60) | RAB9ANPC1SMN1; SMN2ECE1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155333-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180155333-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| EP-3287454-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155333-A1 | Heterocyclic Compound | HCRTR1, HCRTR2, OXTR | RAB9A 2077/4885NPC1 666/4885SMN1; SMN2 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.